Pancreatic cancer patients should be offered early scans to avoid unnecessary surgery, says NICE
NICE recommends the use of a more accurate scan to diagnose and determine the stage of pancreatic cancer in patients.
AbstractBackground.The role of 18F‐fluorodeoxyglucose positron emission tomography (18F‐FDG PET) in the diagnostic algorithm of entero‐pancreatic neuroendocrine neoplasms (EP NENs) is unclear because most available data derive from heterogeneous populations in terms of tumor biology and disease status at time of examination. The aim of this study was to determine the ability of 18F‐FDG PET to identify patients with more aggressive disease among those with advanced EP NENs.Subjects, Materials, and Methods. Patients with advanced EP NENs and known disease status (progressive disease [PD] or stable disease [SD]) accor...
CONCLUSION: The combination of pre-treatment SIb = 600 and S-1 treatment could predict the OS in patients with LAPC undergoing SBRT and sequential S-1 therapy with improved accuracy compared with that of established clinical and radiologic risk models. PMID: 29455086 [PubMed - as supplied by publisher]
For as long as he can remember, Josh Feldman has eagerly embraced the latest technology.Decades ago, his family was the first one on the block with a VCR. Years later, when television went hi-def, he acquired a big-screen TV and signed up for HD service.So after he was diagnosed with lymphoma, it was only natural that Feldman was driven to join clinical trials for a promising new treatment. He would become one of the first UCLA Health patients to receive CAR T therapy. When nothing else worked, the treatment beat back cancer and filled his life with new hope.“Years ago, while doing my own reading after my diagnosis, ...
Patients should be offered early scans to improve the diagnosis of pancreatic cancer and to avoid unnecessary surgery, according to the National Institute for Health and Care Excellence.
Conclusions[18F]FDG PET and acidoCEST MRI studies can be performed simultaneously. The synergistic combination of assessing glucose uptake and tumor acidosis can improve differentiation of a drug-treated group from a control group during drug treatment of a tumor model.
CONCLUSIONSChanges at the PDAC/parenchyma interface may serve as an early predictor of response to therapy. Cancer 2018. © 2018 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
Conclusion Detection of KRAS or p53 mutation in plasma is not an effective screening tool for pancreatic cancer because accumulation of multiple mutations is required for malignant transformation in the pancreas.
CONCLUSIONS: In a prospective study of motion-corrected CBCT in GEJ and pancreas, RMC-CBCT yielded improved organ visibility and localization accuracy for gated treatment at end expiration in the majority of cases. PMID: 29350579 [PubMed - as supplied by publisher]
ConclusionMRI‐guided percutaneous biopsy of pancreatic lesions using an open 1.0T high‐field scanner has high diagnostic accuracy, which is feasible and safe for use in clinical practice.Level of Evidence: 2Technical Efficacy: Stage 2J. Magn. Reson. Imaging 2018.
Conclusion.R0 resection, the goal of neoadjuvant treatment, can be achieved in 70% of patients presenting with locally advanced pancreatic cancer. The median DFS was 31 months (95% CI: 11. 3–51.1). No relationship was found with tumor size, degree of vascular involvement, carcinoembryonic antigen test (CEA), CA 19‐9, degree of tumor regression on scan, fall in CA 19‐9, or SUV on PET scan and subsequent survival.